Angiotensin receptor blocker (ARB) trials in chronic heart failure (CHF): hypotheses tested
| Non-inferiority | Superiority | |||||
|---|---|---|---|---|---|---|
| ARB ⩽ ACE-I | ARB > placebo | ARB > ACE-I | ARB + ACE-II > ACE-I | |||
| ELITE-2 | No | No | Yes (25%, P 90%)2-151 | No | ||
| Val-HeFT | No | No | No | Yes ( 20%, P 90%)2-164 | ||
| CHARM | No | Yes (LVEF ⩽ 0.402-150 18%, P 94% LVEF > 0.402-160 18%, P 86%) | No | Yes ( 18%, P 90%)2-170 | ||
P, power—that is, power of study to detect that risk reduction (for example, Val HeFT has a 90% power to detect a 20% relative risk reduction in mortality with valsartan compared to placebo).
↵2-150 Assuming an annual placebo group event rate of 24%;
↵2-160 assuming an annual placebo group event rate of 13%; ⩽ not significantly inferior to;
↵2-151 assuming a captopril group annual mortality rate of 9.4%;
↵2-164 assuming placebo group annual mortality rate of 12%;
↵2-170 assuming an annual placebo group event rate of 18%.
See table 1 for key to abbreviations.